PT  - JOURNAL ARTICLE
AU  - Pavan, Tommaso
AU  - Steullet, Pascal
AU  - Alemán-Gómez, Yasser
AU  - Jenni, Raoul
AU  - Schilliger, Zoé
AU  - Cleusix, Martine
AU  - Alameda, Luis
AU  - Do, Kim Q.
AU  - Conus, Philippe
AU  - Hagmann, Patric
AU  - Dwir, Daniella
AU  - Klauser, Paul
AU  - Jelescu, Ileana
TI  - Associations Between Blood Markers of the GSH Redox cycle and Brain White Matter Microstructure in Psychosis
AID  - 10.1101/2024.09.02.24312940
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.02.24312940
4099  - http://medrxiv.org/content/early/2024/09/03/2024.09.02.24312940.short
4100  - http://medrxiv.org/content/early/2024/09/03/2024.09.02.24312940.full
AB  - In groups of patients suffering from psychosis, redox dysregulation was reported in both peripheral fluids and brain. It has been hypothesized that such dysregulation, including alterations of the glutathione (GSH) cycle could participate in the brain white matter (WM) abnormalities in schizophrenia (SZ) due to the oligodendrocytes’ susceptibility to oxidative stress (OxS).In this study we aim to assess the differences between 99 psychosis patients (PT) and 86 healthy controls (HC) in GSH-redox peripheral blood markers: GSH peroxidase (GPx), reductase (GR) enzymatic activities and their ratio (GPx/GR-ratio), evaluating the hypotheses that alterations in the homeostasis of the systemic GSH cycle may be associated with pathological mechanisms in the brain WM in PT. We also consider the hypothesis that different homeostatic states of the system (oxidative vs reductive) may reflect differently into the WM microstructure. To do so, we employ the advanced diffusion MRI methods: Diffusion Kurtosis Imaging (DKI) and White Matter Tract Integrity-Watson (WMTI-W), which provide excellent sensitivity to demyelination and neuroinflammation.We show that GPx levels are higher (p=0.00050) in female participants and modulate the effect of aging on the WM. We found differences between PT and HC in the association of GR and mean kurtosis (MK, p=0.028). Namely, lower MK was associated with higher blood GR activity in HC, but not in PT, suggesting that high GR activity (a hallmark of reductive stress) in HC was linked to changes in myelin integrity. Remarkably, GSH-redox peripheral blood markers did not explain the WM anomalies detected in PT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (PCEFP2_194260, to I.J.; 320030_197787 to PH and YA), the National Center of Competence in Research (NCCR) "SYNAPSY - The Synaptic Bases of Mental Diseases" from the Swiss National Science Foundation (51NF40_185897 to KQD & PC) and the Foundation Alamaya. Dr. Alameda is supported by Carigest fellowship and by Frutiger Adrian et Simone fellowship. Dr. Dwir and P. Klauser are supported by Frutiger Adrian & Simone fellowship. The authors have nothing to disclose and there are no conflicts of interest. We are grateful to Gloria Reuteler, Adeline Cottier and Morgane Baumgartner for expert technical assistance. Dr Luis Alameda thanks the Foundation Adrian and Simone Frutiger and Carigest SA Foundation for their supportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local Ethics Committee of the Canton of Vaud (Switzerland) under authorization numbers CER-VD 382/11 and 2018-01731.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will not be available, however, the models and scripts used will published online https://github.com/tmspvn